Articles tagged with Hormone Therapy
A large clinical trial found that hormone replacement therapy with estrogen and progestin did not increase or decrease the risk of stroke among postmenopausal women with heart disease. The study's lead author cautioned that the results may not apply to all women taking hormone therapy, and more research is needed.
A study by UK fertility experts found that natural cycle IVF can achieve comparable results to conventional treatment in 60-70% of cases, while reducing costs and risks. The approach is suitable for women with regular menstrual cycles and fallopian tube problems, but not for those with irregular ovulation or ICSI requirements.
New research reveals estrogen can regress tamoxifen-resistant breast tumors by increasing apoptosis. Low levels of estradiol also inhibit tumor growth in raloxifene-resistant breast cancer cells.
New data from the Nurses' Health Study suggests hormone replacement therapy reduces heart attack risk by 40% in postmenopausal women. However, taking higher doses of estrogen or combination therapy with progestin may increase stroke risk by 30%.
Venlafaxine has been shown to alleviate hot flashes in postmenopausal women, including those with breast cancer, by reducing symptoms by 61%. The study found that a daily dose of 37.5-75mg was optimal for effect, with mild improvements in quality of life and no significant impact on libido.
A novel therapy employing the immune system to attack prostate cancer cells has been found to slow disease progression in some men and decrease PSA levels. The study's results show that modified dendritic cells can train lymphocytes to recognize prostate cancer cells, leading to a stronger immune response.
Women are twice as likely to experience migraine without aura during the first two days of their menstrual cycle. The study also found a higher risk of migraine in the two days before menstruation begins and a lower risk around ovulation.
The symposium aims to provide state-of-the-art information on breast cancer research. Five plenary speakers will discuss various topics, including targeted therapies and hormone replacement therapy.
A speech-language pathologist is presenting a successful program that helps male-to-female transgender clients acquire a more feminine-sounding voice. The one-year intensive therapy focuses on practical skills like speech rate, intonation, and non-verbal communication to improve the client's overall perception as a woman.
A new study suggests that losartan, a type of hypertension medication, may improve sexual function in men with high blood pressure. After 12 weeks of treatment, 88% of hypertensive males with sexual dysfunction reported improvement in at least one area of sexuality. The drug also showed promise in improving overall quality of life.
A University of California, San Francisco study found that the herbal supplement PC-SPES significantly reduces PSA levels in men with hormone-independent disease, providing a new treatment option. The study also shows promise for shrinking tumors and improving quality of life.
A large study of 381 postmenopausal women found no association between high fat intake and increased estrogen levels, contrary to long-held assumptions. The researchers concluded that reducing fat intake to lower hormone levels is unlikely to be a useful strategy in preventing breast cancer.
Dr. Sherwin's research suggests that estrogen replacement therapy prevents some of the decline in verbal memory and ability to learn new material in postmenopausal women. This effect has been observed even in women who underwent surgical removal of their ovaries, which led to a sudden drop in estrogen levels.
A study found that only 18.5% of patients with fragility fractures received a proper osteoporosis diagnosis, and even fewer were treated accordingly. This gap in care represents a significant lost opportunity to build bone mass and reduce fracture risk among Canada's aging population.
A new nomogram developed at Memorial Sloan-Kettering Cancer Center predicts outcomes based on disease factors such as stage, PSA level, and radiation dosage. The tool demonstrates improved accuracy in estimating treatment efficacy compared to existing models.
The ECCO organisation urges a streamlined process for new cancer drugs, citing long and cumbersome procedures that hinder patient access. Experts warn of the need for harmonisation between regulatory agencies to avoid duplication and shorten the approval process.
Adjuvant treatments with radiotherapy, chemotherapy, and hormone treatment tamoxifen can prevent late recurrences in breast cancer patients. The new findings show a significant decrease in deaths from breast cancer in middle-aged women, with a 30% fall over the past decade in the UK.
Researchers are developing BioMEMs, implant materials and devices that integrate micro- and nanoscale features to affect cellular function. These therapeutic systems use chip technology, material science, and bioengineering to grow heart cells in culture and protect implanted cells with precision.
The estimated total first year costs for diagnosing, treating, and managing FMMA range from $410 for insulin resistance to $7,368 for abnormal fat distribution, with second-year costs ranging from $115 to $3,895 depending on the symptom being treated.
Researchers found that combining radiation therapy with androgen suppression therapy significantly reduced the risk of PSA failure in men with intermediate- and high-risk prostate cancer. The treatment showed efficacy even in low-risk patients, suggesting a potential benefit for all early-stage prostate cancer patients.
Renowned scientists and clinicians will discuss recent advances in breast cancer science and treatment, including new developments in imaging techniques, hormone replacement therapy, and alternative therapies. The symposium will feature prominent speakers from top medical institutions.
A new study published in the New England Journal of Medicine found that a testosterone patch improved sexual function and psychological well-being in surgically postmenopausal women. The study showed that treatment with higher doses of testosterone substantially improved outcomes, while lower doses had less effect.
A study found that a testosterone skin patch can relieve impaired sexual functioning in surgically menopausal women. The patch restored normal testosterone levels, leading to improved sexual activity and pleasure, as well as overall psychological well-being. Adverse side effects were minimal.
A six-month study found that isoflavone-rich soy protein isolate attenuated bone loss in the lumbar spine of perimenopausal women. The treatment group showed a significant reduction in bone mineral density and content compared to the control group. This suggests that soy may be a useful adjunct therapy for preventing osteoporosis in wo...
A major study found that hormone replacement therapy did not slow the progression of heart disease in older women, despite improvements in cholesterol levels. The Estrogen Replacement and Atherosclerosis (ERA) trial used cardiac catheterization to measure narrowing in the heart's arteries caused by a buildup of cholesterol.
Researchers found two stages of age-related deterioration of sleep quality: the first between young adulthood (16-25) and mid-life (35-50), and the second after age 50. Changes in sleep quality were mirrored by changes in hormone secretion, particularly growth hormone, which declined significantly with age.
Postmenopausal women who took n-3 fatty acid-enriched supplements experienced a 26% reduction in serum triglycerides, while those not taking HRT saw a 36% decrease. This suggests that fish-oil therapy may benefit postmenopausal women regardless of hormone replacement therapy use.
A team of Dutch doctors and scientists have found a possible link between testosterone and endometrial cancer, with high local pelvic androgen levels and increased expression of androgen receptors detected in patients. The study suggests that androgens may be a co-factor in the development of endometrial cancer.
For couples experiencing unexplained infertility, a five-step treatment program has shown a 75% success rate in conception. The program includes careful evaluation and escalating steps such as antibiotics, intra-uterine insemination, and IVF with ICSI.
Researchers found that long-term anticoagulant use doesn't reduce venous thromboembolism or death after knee or hip surgery. A new study shows promise in treating scleroderma with recombinant human relaxin, reducing skin thickening and improving mobility.
Abarelix depot-M successfully suppresses testosterone levels, achieving suppression by day 8 and maintaining it from day 29 through day 85. The studies validated PRAECIS' core technology and demonstrate a potentially new treatment option for prostate cancer.
A Phase III trial shows long-term hormone suppression can control recurrence and improve survival in prostate cancer patients. The treatment significantly reduces disease-free survival, local progression, and freedom from distant metastasis.
A large clinical trial is underway at UCSF to study a combination drug therapy for osteoporosis, using recombinant human parathyroid hormone (1-84) and alendronate. The trial aims to combine agents that speed up bone formation and resorption with those that slow down resorption, resulting in a net gain of bone strength.
Researchers at UCSF found that excessive water consumption during marathons can lead to fatal brain swelling and fluid leakage into the lungs, a condition known as hyponatremia. Intravenous salt treatment has been shown to be effective in treating hyponatremia.
Researchers present promising treatments for renal cell carcinoma using 5-aminolevulinic acid fluorescence detection, as well as a vaginal mucosal vaccine for recurrent urinary tract infections. Additionally, studies investigate the long-term health-related quality of life impacts of different prostate cancer therapies.
A study published in Urology suggests that patients treated with radiation therapy for prostate cancer have a high chance of being disease-free after four years, with minimal risk of recurrence. Patients with favorable prognoses also show a lower risk of treatment failure sooner than those with less favorable prognoses.
A study by Duke University Medical Center has shown that blocking a key enzyme pathway can prevent the onset of heart failure. The researchers found that blocking ß-adrenergic receptor kinase (ßARK) after a heart attack preserves heart function, providing a promising new avenue for treating and preventing heart failure.
Researchers discovered a group of genes controlled by leptin that regulate fat tissue mass and body weight. The study found that leptin influences fatty acid synthesis through the regulation of SREBP-1, identifying potential therapeutic targets for treating obesity.
Research published in the American Journal of Clinical Nutrition found that tea drinkers had a 5% greater mean BMD than non-tea drinkers, equating to a 10-20% decline in fracture risk. Isoflavonoids in tea are thought to contribute to this positive effect.
A new study of 309 older women found that hormone replacement therapy (HRT) did not slow the progression of heart disease. HRT lowered cholesterol, but this benefit did not translate to a measurable impact on artery narrowing.
The conference features expert speakers discussing attitudinal healing, the importance of spirituality in maintaining good health, and navigating the confusing signals of menopause. Women can learn how to incorporate spiritual practices into their daily lives and make informed choices about their health.
A new anti-angiogenesis drug delivered as a nose drop has shown promising results in treating AIDS-related Kaposi's Sarcoma. The study found a major response rate of 36% among patients, with some experiencing complete remission and others experiencing stabilization or regression of their disease for several weeks after stopping treatment.
A study of postmenopausal women in Los Angeles County found that long-term use of hormone replacement therapy combining estrogen and progestin increases breast cancer risk by 24%. The risk was highest for sequential therapy, but continuous combined therapy showed lower risks. Researchers suggest lowering doses to decrease disease risk.
Researchers at the University of North Carolina at Chapel Hill conducted a double-blind study to investigate the effectiveness of synthetic human hormone secretin on children with autism. The study found no difference between groups receiving secretin and placebo, suggesting a potential placebo effect.
A recent study led by Drs. Bodfish and Sandler found no significant improvement in behavior among children with autism treated with synthetic secretin, compared to a placebo. The researchers emphasized the need for further studies to determine the hormone's potential benefits and risks.
A Yale child psychiatrist has supported the results of an autism treatment study that found a popular drug to be ineffective in controlling autistic symptoms. The study, published in the New England Journal of Medicine, looked at the effect of secretin on 56 children with autism and similar disorders and found no improvement.
Researchers at UroGenesys identify a novel cell-surface antigen called STEAP, expressed on prostate cancers but rarely in non-prostate tissues. The discovery suggests STEAP may be a promising target for new treatments and diagnostic tools to monitor prostate cancer progression.
Researchers at Memorial Sloan-Kettering Cancer Center challenge current understanding of prostate cancer treatment by showing that testosterone withdrawal triggers a dormant state in tumor cells, rather than causing widespread cell death. This study offers new hope for developing targeted therapies to combat recurrent prostate cancer.
A recent study of Ontario family physicians and gynecologists found that over 98% of respondents prescribed hormone replacement therapy (HRT) to prevent osteoporosis, with almost 90% citing coronary artery disease as a consideration. The most significant reasons not to prescribe HRT included breast cancer concerns and strong family his...
A study led by University of Southern California researchers found that tamoxifen therapy for breast cancer increases the risk of endometrial cancer by about 50 percent. The risk is higher in women who have previously used estrogens, are overweight, or have a history of estrogen replacement therapy.
A Yale study suggests that breast cancer patients with BRCA1 or BRCA2 genes are at higher risk of late relapses after treatment. Women with these mutations respond well to initial therapy but may develop second tumors years later.
Researchers found that patients who previously received hormone therapy with tamoxifen, had no prior chemotherapy, and had limited metastases were more likely to live longer after high-dose chemotherapy with transplant. This study suggests that closely monitoring high-risk patients can improve treatment outcomes.
A study published in the New England Journal of Medicine shows that adding spironolactone to standard treatment regimens for heart failure reduced mortality by 30 percent. The research confirms aldosterone's role in heart failure pathophysiology and opens the door to more effective treatment options.
A new study suggests that estrogen supplementation in postmenopausal women may slow the progression of periodontal disease, protecting their teeth. The research found that estrogen deficiency and osteopenia/osteoporosis speed oral bone loss following menopause, leading to tooth loss.
A study found that large doses of vitamin C can reduce levels of stress hormones in the blood and boost the immune system. Vitamin C also reduced indicators of physical and emotional stress, such as loss in body weight and enlargement of the adrenal glands.
A study found that untreated hypothyroidism in pregnant women is associated with lower IQ scores in their children. Children of mothers treated for the condition showed similar intelligence levels to those born to healthy mothers. Early detection and treatment may mitigate the negative effects.
A Harvard Medical School study reveals that physician guidelines for estrogen replacement therapy fail to address women's concerns and needs. Researchers found that patients value healthcare provider opinions, media influences, and friend opinions when making decisions about hormone replacement therapy.
Researchers at the University of Pennsylvania School of Medicine discovered that anti-diabetic agents can significantly reduce symptoms of inflammatory bowel disease in mice. The study suggests that these compounds may be an effective treatment for humans with ulcerative colitis, a debilitating disorder affecting millions worldwide.
A new report from the National Cholesterol Education Program (NCEP) states that cholesterol lowering in elderly Americans can significantly reduce heart disease and stroke risk. The NCEP recommends lowering cholesterol through a healthy diet, exercise, and weight management.
A large-scale study by the University of Chicago found that immunotherapy, a treatment aimed at preventing recurrent miscarriage, is not effective. Women who received this treatment had more and later miscarriages compared to those receiving a placebo.